MetabolicMolecular Weight: 4000Reviewed: 2026-04-22

Cagrilintide

AM833

A long-acting amylin receptor agonist under investigation for weight management. Promotes significant weight loss through appetite suppression.

Quick Answer

Cagrilintide is the amylin half of the next-generation obesity conversation. Searchers want to understand what amylin signaling adds on top of GLP-1, why CagriSema is different from tirzepatide, and where the evidence currently sits.

Mechanism

Long-acting amylin receptor agonist that suppresses appetite and promotes weight loss. Works by mimicking the effects of amylin, a hormone that regulates food intake.

Half-Life

7-8 days

Administration

Subcutaneous

Technical Protocol

Cagrilintide: Comprehensive Research Guide

Overview

Cagrilintide (AM833) is a long-acting amylin receptor agonist currently under investigation for weight management. Amylin is a hormone co-secreted with insulin that helps regulate food intake and glucose metabolism. Cagrilintide mimics these effects with an extended half-life.

Mechanism of Action

Amylin Receptor Agonism

Appetite Suppression: Reduces food intake and appetite
Gastric Emptying: Delays gastric emptying
Satiety: Promotes feelings of fullness
Glucose: May improve glucose control

Weight Loss

Significant Loss: Promotes substantial weight loss
Sustained: Long-acting formulation provides sustained effects
Combination: Often studied in combination with semaglutide

Research Applications

Weight Management

Obesity: Treatment of obesity
Weight Loss: Significant weight loss in trials
Long-term: Potential for long-term weight management
Combination: Research into combination therapies

Dosage

Research: 0.3-4.5 mg weekly
Typical: 2.4-4.5 mg weekly
Administration: Subcutaneous injection
Frequency: Once weekly

Side Effects

GI Effects: Nausea, vomiting, diarrhea, constipation
Mild to Moderate: Generally mild to moderate
Tolerance: May improve with continued use

Storage

Temperature: 2-8°C (refrigerated)
Do Not Freeze: Protect from freezing
Light: Protect from light

This information is for research and educational purposes only. Cagrilintide is investigational and not approved for human use.

Frequently Asked Questions

Is cagrilintide the same as tirzepatide?

No. Tirzepatide is a single molecule that hits GLP-1 and GIP receptors. Cagrilintide targets the amylin receptor family, which is a separate hormone system. CagriSema combines cagrilintide with semaglutide, which is a different architecture entirely from tirzepatide.

What does cagrilintide add on top of semaglutide?

Amylin-receptor engagement acts on gastric emptying and central satiety pathways that are distinct from GLP-1 signaling. The rationale for CagriSema is complementary satiety mechanisms, not simply a higher GLP-1 dose.

How should Cagrilintide be stored?

Store at 2-8°C, do not freeze

Continue the Research Path

Metabolic Topic Hub

Comparisons

Regulatory Hub

Cagrilintide and CagriSema: Amylin Analog Research Explained

Evidence-aware guide to cagrilintide and the CagriSema (cagrilintide + semaglutide) combination: amylin receptor biology, REDEFINE trial context, and how it differs from standalone GLP-1 therapy.

Triple Agonists Explained: GLP-1, GIP, and Glucagon in One Molecule

Map of the triple-agonist class (retatrutide and peers): why three receptors beat two, what the TRIUMPH data suggested, and how to compare with tirzepatide, CagriSema, and survodutide.

Semaglutide vs Retatrutide: Single vs Triple Receptor Agonism

Mechanistic and evidence-based comparison of semaglutide (selective GLP-1) and retatrutide (GLP-1/GIP/glucagon triple agonist): receptor biology, clinical data maturity, and where each compound fits.

GLP-1 Agonists: Semaglutide, Tirzepatide & Metabolic Regulation

Scientific overview of GLP-1 and dual-agonist metabolic peptides, mechanism, outcomes, and limitations.

Answer-First Research Snapshot

Evidence

The strongest opportunity is to explain amylin vs incretin biology clearly and place CagriSema on the receptor map alongside tirzepatide, survodutide, and retatrutide.

Dosage Context

Dose questions usually reflect curiosity about CagriSema combination titration and tolerability relative to semaglutide monotherapy. Framing should stay research-oriented and avoid protocol speculation.

Status

NDA was submitted in late 2025 under regulatory review. This page should be framed as high-interest, evidence-maturing, and status-sensitive.

Amylin and GLP-1 are different receptor families; CagriSema is not a tirzepatide analog.

Efficacy framing should stay conservative and cross-trial comparisons cautious.

Place cagrilintide on the wider metabolic receptor map: tirzepatide (dual incretin), survodutide (GLP-1/glucagon), retatrutide (triple).

Related Metabolic Peptides

metabolic